+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
FEMALE
Healthy Volunteers
ID07173127

Study of Ryeqo, a New Hormonal Treatment with GnRH Antagonist for Uterine Fibroids and Endometriosis, Evaluating Its Effects on Blood Clotting Factors

Led by University Hospital, Geneva · Updated on 2026-04-29

30

Participants Needed

1

Research Sites

12 weeks

Total Duration

AI-Summary

What This Trial Is About

Uterine fibroids and endometriosis are common conditions among women of reproductive age that can cause pelvic pain and abnormal uterine bleeding. This research evaluates the effects of a novel combined hormonal therapy called Ryeqo, which contains a GnRH antagonist Relugolix along with low-dose estradiol and progesterone, on blood clotting markers to estimate the risk of venous thromboembolism VTE. Understanding this risk could help tailor hormonal treatments based on each womans personal health profile. Ryeqo is taken as an oral pill containing 40 mg of Relugolix combined with 1 mg estradiol and 0.5 mg norethisterone acetate. The treatment suppresses ovulation while maintaining low but steady hormone levels to reduce symptoms and side effects. The study involves two visits before starting Ryeqo and three months after treatment begins. Blood samples and questionnaires on demographics and clinical symptoms are collected at both visits to monitor changes in hemostasis parameters. Participants will undergo blood tests measuring various coagulation markers such as activated protein C resistance, sex hormone-binding globulin, and thrombin generation at baseline and after three months of treatment. Researchers will analyze these to assess any changes linked to VTE risk. The total study duration for each participant is three months, during which safety and symptom questionnaires are also completed to monitor effects and tolerability of the therapy.

CONDITIONS

Brief Title

The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters

Research Team

M

Manuela Viviano, MD

J

Justine Hugon-Rodin

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here